Clinical Trial Update: UC-MSCs in the Treatment of Severe and Critical COVID-19 Patients With Refractory Hypoxia [Phase 3]

View source ↗

Summary

Phase 3 trial exploring UC-MSCs for severe and critical COVID-19 with refractory hypoxia; status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia

Drugs mentioned

• Umbilical Cord-derived Mesenchymal Stem Cells (UC-MSCs) (mesenchymal stem cells)

Snippet

Sponsor: Shanghai East Hospital | Conditions: Mesenchymal Stem Cell, COVID-19 Pneumonia | Phase 3 | Status: UNKNOWN